Innate Pharma S.A. ADR (IPHA) Stock Price, Quote & News

Company Profile

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 4 30 30 30 30

Fax: 33 4 30 30 30 00

Website: www.innate-pharma.com

Address:

117, Avenue de Luminy, BP 30191, Marseille, France

MochiMeerkat Feb. 23 at 5:39 PM

.@SqueezeSharkie moving different. .Ice-cold vision, pure substance. Costs you nothing but a tap, follow him now!! $TOVX $SPRB $IPHA $EVGN *^

0 · Reply

FadeObserver Feb. 18 at 8:13 AM

$IPHA Innate Pharma provides immuno-oncology therapies, facing pipeline success binary and dependent on partnership milestones [citation:historical].

0 · Reply

wicklars Feb. 17 at 8:35 AM

$IPHA Pre-revenue biotech; early-stage

0 · Reply

peepthestamp Feb. 13 at 6:59 PM

$IPHA

0 · Reply

OfficialStocktwitsUser Feb. 2 at 11:47 PM

$IPHA RSI: 50.00, MACD: -0.0012 Vol: 0.03, MA20: 1.78, MA50: 1.81 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

CapitalSignalMatrix Dec. 27 at 8:24 AM

$IPHA Investor attention is skewing toward repeatable operating performance instead of aspirational projections. Forecast reliability has room to improve materially. Credible progress tends to compress risk premiums. Momentum becomes sustainable only when delivery keeps pace.

0 · Reply

neo55 Dec. 19 at 3:36 PM

$IPHA look at pattern dips to 1.7 goes back to 2.50 4 x this year buy low

0 · Reply

SuperGreenToday Dec. 19 at 3:28 PM

$IPHA

0 · Reply

javier0304 Nov. 28 at 10:36 AM

$IPHA Time to get in this

0 · Reply

UgoGreg Nov. 11 at 4:35 PM

$IPHA https://youtu.be/rUHW24bmO0c

0 · Reply

Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026

2026-02-19T06:00:00.000Z - 4 days ago

Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026

Thu, 19 Feb 2026 01:00:00 -0500 - 4 days ago

Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026

2026-02-18T06:06:00.000Z - 5 days ago

Innate Pharma SA: Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference

Wed, 18 Feb 2026 01:00:00 -0500 - 5 days ago

Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference

2026-01-07T06:06:00.000Z - 6 weeks ago

Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025

2026-01-07T06:00:00.000Z - 6 weeks ago

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025

Wed, 07 Jan 2026 01:00:00 -0500 - 6 weeks ago

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025

2025-12-22T06:06:00.000Z - 2 months ago

Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025

2025-12-22T06:00:00.000Z - 2 months ago

Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025

Mon, 22 Dec 2025 01:00:00 -0500 - 2 months ago

Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025

2025-12-11T06:06:00.000Z - 2 months ago

Innate Pharma SA: Innate Pharma Releases Its 2026 Financial Calendar

2025-12-11T06:00:00.000Z - 2 months ago

Innate Pharma Releases Its 2026 Financial Calendar

Thu, 11 Dec 2025 01:00:00 -0500 - 2 months ago

Innate Pharma Releases Its 2026 Financial Calendar

2025-11-28T06:06:00.000Z - 3 months ago

Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025

Fri, 28 Nov 2025 01:00:00 -0500 - 3 months ago

Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025

2025-11-17T06:06:00.000Z - 3 months ago

Innate Pharma SA: Innate Pharma to Present at Jefferies Global Healthcare Conference

Mon, 17 Nov 2025 01:00:00 -0500 - 3 months ago

Innate Pharma to Present at Jefferies Global Healthcare Conference

2025-11-13T22:21:36.000Z - 3 months ago

Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript

2025-11-13T12:05:36.000Z - 3 months ago

Innate Pharma (IPHA) Reports Significant Revenue Decline in 9M 2025

2025-11-13T11:32:53.000Z - 3 months ago

Innate Pharma reports 9M results

Thu, 13 Nov 2025 01:00:00 -0500 - 3 months ago

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

2025-11-10T11:30:42.000Z - 3 months ago

Innate Pharma (IPHA) Gains FDA Approval to Advance Phase 3 Lacutamab Trial

2025-11-10T06:00:00.000Z - 3 months ago

Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

Mon, 10 Nov 2025 01:00:00 -0500 - 3 months ago

Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

Wed, 05 Nov 2025 01:00:00 -0500 - 3 months ago

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates

2025-10-29T12:33:06.000Z - 4 months ago

Innate Pharma (IPHA) Upgraded to Buy by HC Wainwright & Co. | IPHA Stock News

2025-10-29T11:43:31.000Z - 4 months ago

This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

2025-10-29T11:31:13.000Z - 4 months ago

BTIG Reiterates Buy Rating for Innate Pharma (IPHA) with $8 Target | IPHA Stock News

2025-10-28T22:21:51.000Z - 4 months ago

Innate Pharma S.A. (IPHA) Analyst/Investor Day Transcript

2025-10-28T22:12:53.000Z - 4 months ago

Innate Pharma S.A. (IPHA) Analyst/Investor Day - Slideshow

Tue, 14 Oct 2025 01:00:00 -0400 - 4 months ago

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

2025-09-18T14:00:34.000Z - 5 months ago

This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

2025-09-18T12:34:36.000Z - 5 months ago

IPHA: Leerink Partners Downgrades Innate Pharma, Lowers Price Target | IPHA Stock News

2025-09-18T12:00:14.000Z - 5 months ago

Innate Pharma (IPHA) Downgrade: What Investors Need to Know | IPHA Stock News

2025-09-18T07:00:54.000Z - 5 months ago

Innate Pharma SA (IPHA) (H1 2025) Earnings Call Highlights: Strategic Focus and Financial ...

2025-09-18T05:01:25.000Z - 5 months ago

Half Year 2025 Innate Pharma SA Earnings Call Transcript

2025-09-17T18:45:13.000Z - 5 months ago

Innate Pharma S.A. GAAP EPS of -€0.25, revenue of €4.9M

Wed, 17 Sep 2025 11:43:48 -0400 - 5 months ago

Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript

2025-09-17T15:01:03.000Z - 5 months ago

Innate Pharma S.A. 2025 Q2 - Results - Earnings Call Presentation

2025-09-17T08:46:41.000Z - 5 months ago

Innate Pharma H1 Net Loss Shrinks, Plans 30% Workforce Cut, Stock Drops

2025-09-17T08:32:11.000Z - 5 months ago

Earnings Scheduled For September 17, 2025

Wed, 17 Sep 2025 01:00:00 -0400 - 5 months ago

Innate Pharma Reports First Half 2025 Business Update and Financial Results

2025-09-17T05:00:00.000Z - 5 months ago

Innate Pharma Reports First Half 2025 Business Update and Financial Results

2025-09-16T13:15:59.000Z - 5 months ago

Innate Pharma SA (IPHA) Q2 2025 Earnings Report Preview: What To Look For

Mon, 15 Sep 2025 01:00:00 -0400 - 5 months ago

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

2025-09-15T05:00:00.000Z - 5 months ago

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

Wed, 10 Sep 2025 04:30:00 -0400 - 5 months ago

Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update

2025-09-02T05:00:00.000Z - 6 months ago

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025

Tue, 29 Jul 2025 01:00:00 -0400 - 7 months ago

Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference

Tue, 17 Jun 2025 01:00:00 -0400 - 8 months ago

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

Fri, 13 Jun 2025 01:00:00 -0400 - 9 months ago

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

Tue, 27 May 2025 01:00:00 -0400 - 9 months ago

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

Fri, 23 May 2025 01:00:00 -0400 - 9 months ago

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

Fri, 23 May 2025 01:00:00 -0400 - 9 months ago

Outcome of Innate Pharma's 2025 Annual General Meeting

Mon, 19 May 2025 01:00:00 -0400 - 10 months ago

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

Thu, 15 May 2025 01:00:00 -0400 - 10 months ago

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

Tue, 13 May 2025 13:51:34 -0400 - 10 months ago

Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript

2025-05-13T17:51:34.000Z - 10 months ago

Innate Pharma S.A. 2025 Q1 - Results - Earnings Call Presentation

2025-05-13T17:47:49.000Z - 10 months ago

Innate Pharma S.A. reports Q1 results

2025-05-13T06:57:40.000Z - 10 months ago

Innate Pharma reports Q1 results

Tue, 13 May 2025 01:00:00 -0400 - 10 months ago

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

Tue, 06 May 2025 01:00:00 -0400 - 10 months ago

Innate Pharma announces conference call and webcast for Q1 2025 business update

Wed, 30 Apr 2025 11:30:00 -0400 - 10 months ago

Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F

Tue, 29 Apr 2025 15:00:00 -0400 - 10 months ago

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

Thu, 24 Apr 2025 01:35:00 -0400 - 10 months ago

Innate Pharma Announces €15M Investment by Sanofi

Wed, 23 Apr 2025 01:00:00 -0400 - 10 months ago

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

Wed, 16 Apr 2025 01:00:00 -0400 - 11 months ago

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

Wed, 16 Apr 2025 01:00:00 -0400 - 11 months ago

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

Apr 3, 2025, 1:00 AM EDT - 11 months ago

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

Mar 27, 2025, 4:49 PM EDT - 11 months ago

Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 2:00 AM EDT - 11 months ago

Innate Pharma Reports Full Year 2024 Financial Results and Business Update

Mar 26, 2025, 2:00 AM EDT - 11 months ago

Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting

Mar 25, 2025, 2:00 AM EDT - 11 months ago

Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference

Mar 21, 2025, 9:10 AM EDT - 1 year ago

Innate Pharma: Moving Into The Padcev Space

Mar 20, 2025, 2:00 AM EDT - 1 year ago

Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

Feb 27, 2025, 1:00 AM EST - 1 year ago

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

Feb 20, 2025, 11:39 AM EST - 1 year ago

Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion

$Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome$

Feb 17, 2025, 1:02 AM EST - 1 year ago

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

Jan 27, 2025, 1:00 AM EST - 1 year ago

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

Jan 21, 2025, 1:00 AM EST - 1 year ago

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Jan 10, 2025, 1:00 AM EST - 1 year ago

Innate Pharma Announces Transformative Strategy to Accelerate Growth

Dec 20, 2024, 1:00 AM EST - 1 year ago

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 1:00 AM EST - 1 year ago

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Dec 6, 2024, 1:00 AM EST - 1 year ago

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

MochiMeerkat Feb. 23 at 5:39 PM

.@SqueezeSharkie moving different. .Ice-cold vision, pure substance. Costs you nothing but a tap, follow him now!! $TOVX $SPRB $IPHA $EVGN *^

0 · Reply

FadeObserver Feb. 18 at 8:13 AM

$IPHA Innate Pharma provides immuno-oncology therapies, facing pipeline success binary and dependent on partnership milestones [citation:historical].

0 · Reply

wicklars Feb. 17 at 8:35 AM

$IPHA Pre-revenue biotech; early-stage

0 · Reply

peepthestamp Feb. 13 at 6:59 PM

$IPHA

0 · Reply

OfficialStocktwitsUser Feb. 2 at 11:47 PM

0 · Reply

CapitalSignalMatrix Dec. 27 at 8:24 AM

0 · Reply

neo55 Dec. 19 at 3:36 PM

$IPHA look at pattern dips to 1.7 goes back to 2.50 4 x this year buy low

0 · Reply

SuperGreenToday Dec. 19 at 3:28 PM

$IPHA

0 · Reply

javier0304 Nov. 28 at 10:36 AM

$IPHA Time to get in this

0 · Reply

UgoGreg Nov. 11 at 4:35 PM

$IPHA https://youtu.be/rUHW24bmO0c

0 · Reply

Hekinsieden Nov. 10 at 11:50 PM

$IPHA $BNAI $GLTO $CAPS

0 · Reply

topstockalerts Nov. 10 at 11:10 PM

Top Gainers PT2 $SWAG $GREE $IRWD $SKYT $IPHA

0 · Reply

topstockalerts Nov. 10 at 9:42 PM

Top Gainers PT2 $SWAG $GREE $IRWD $SKYT $IPHA

0 · Reply

MS_Tammy Nov. 10 at 8:32 PM

$IPHA $BNAI $GLTO $CAPS me done for the day.,Well done to everyone who made money today ..I see you all tomorrow and thanks for your trust and support as usual..follow us to make money. All free info on Stocktwits.. do not pay anyone your hard earned money for useless alerts.

9 · Reply

neo55 Nov. 10 at 8:24 PM

$IPHA I see this going to 3 by end of week GL

0 · Reply

A1DAYTRADER Nov. 10 at 8:15 PM

$IPHA 👀🤫💵 $HKIT 🤫🚀👀 $VCIG $SELX $GLTO $MOVE.X $BNAI $MSGY

0 · Reply

UltimateWackDumbtrader27 Nov. 10 at 8:07 PM

$IPHA FDA clearance news of phase 3s usually have a brutal bullish run.

0 · Reply

notreload_ai Nov. 10 at 5:08 PM

$IPHA is moving forward with the TELLOMAK 3 trial for lacutamab in advanced cutaneous T-cell lymphomas (CTCL), including Sézary syndrome (SS) and Mycosis fungoides (MF). https://notreload.xyz/fda-clears-lacutamab-confirmatory-phase-3-ctcl-trial-protocol/

0 · Reply

BearTamerTrading Nov. 10 at 4:44 PM

🚀 Premarket Power Plays — Bear Tamer Trading Community Wins 🔥 Part 2/3 The following plays were called LIVE during premarket before the crowd: 🔥 $GLTO — 323% move off cell-therapy data re-rating/press release 🔥 $OGN — Broad Women’s Health spin-out momentum & product update 🔥 $IPHA — Pipeline progress announcement in dermatology/auto-immune space 🔥 $RUM — Video-platform commentary surge & speculative breakout play. Members were already in position before the volume spike 💪 If you missed it, watch the replay for proof — testimonials are in the comments ⬇️ 🎥 Replay Link: https://www.youtube.com/live/vlYDstPoN2w?si=sy_JgV1cEZVx78Vf

4 · Reply

UltimateWackDumbtrader27 Nov. 10 at 4:43 PM

$IPHA hereeeee halty up, halty up, halty up…..here boy….

0 · Reply

Market Cap	151.86M
Revenue (ttm)	21.77M
Net Income (ttm)	-53.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-245.89%
Debt to Equity Ratio	5.25

Volume	11,362
Avg Vol	23,890
Day's Range	N/A - N/A
Shares Out	93.74M
Stochastic %K	17%
Beta	-0.02
Analysts	Sell
Price Target	$5.00